Earlier this month, MindMed’s Phase 2b study of its lysergide D-tartrate candidate (dubbed MM120, which we also refer to simply as ‘LSD’ here) in adults with moderate to severe generalised anxiety disorder (GAD) was published in JAMA (Robison et al., 2025). The study saw 198 patients receive a single dose of one of the following: 25 µg LSD, 50 µg LSD, 100 µg LSD, 200 µg LSD, or placebo.
